Effect of second line treatment with S-1 and thalidomide in patients with advanced pancreatic cancer
10.3760/cma.j.issn.1674-1935.2015.04.003
- VernacularTitle:替吉奥联合沙利度胺二线治疗晚期胰腺癌的疗效观察
- Author:
Jin ZHAO
;
Xingde LI
;
Guangyu SUN
;
Jun ZHOU
;
Ying SHI
;
Yongsheng LI
;
Jinghua GAO
- Publication Type:Journal Article
- Keywords:
Pancreatic neoplasms;
Drug therapy;
Comparative effectiveness research;
S-1;
Thalidomide
- From:
Chinese Journal of Pancreatology
2015;15(4):229-232
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigates the efficacy and tolerability of second line treatment with S-1 plus thalidomide in patients with advanced pancreatic cancer.Methods Sixty patients hospitalized in Department of Oncology of Cangzhou Central Hospital from July 2010 to October 2012 were included in this study.All the patients were diagnosed as having pancreatic carcinoma.The patients were randomly divided into two groups,one group was treated with S-1 alone,and the other group was treated with S-1 plus thalidomide.Then the efficacy and toxicity of two groups was evaluated.Results The disease control rates were 36.7％ and 46.7％ in the S-1 alone group and the S-1 plus thalidomide group,and the difference between the two groups was not statistically significant (P =0.31).The progression free survival (PFS) was 2.9 months and 3.3 months,and the difference between the two groups was statistically significant (P ＜ 0.05),the Karnofsky score,pain,sleep and weight improvement rate was 63.3％,46.7％,66.7％ and 53.3％ in combination group,which were significantly better than those in control group (30.0％,13.3％,30.0％ and 20.0％),and the difference between the two groups was statistically significant (P ＜ 0.05).The major adverse events were nausea,vomiting,fatigue and drowsiness,mainly of grades Ⅰ ～ Ⅱ.Conclusions S-1 plus thalidomide as second line treatment of pancreatic cancer can prolong the PSF of patients with advanced pancreatic cancer with excellent safety,and patients' quality of life is also improved.
